Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab
机构:[1]Hebei Med Univ, Hosp 4, Breast Ctr, Shijiazhuang, Hebei, Peoples R China临床科室外一科河北医科大学第四医院[2]Hebei Med Univ, Hosp 4, Dept Pathol, 12 Jiankang Rd, Shijiazhuang 050035, Hebei, Peoples R China医技科室病理科河北医科大学第四医院[3]Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Sichuan, Peoples R China四川大学华西医院
Metadherin (MTDH), also known as astrocyte elevated gene-1 (AEG-1), is an oncoprotein closely related to the development of breast cancer. However, few studies have been done on the expression and clinical significance of MTDH in human epidermal growth factor receptor-2 (HER-2) positive breast cancer patients. This study aimed to investigate the expression of MTDH in locally advanced HER-2 positive breast cancer, and evaluate the clinical significance of MTDH in predicting the prognosis of patients with HER-2 positive advanced breast cancer who received the neoadjuvant chemotherapy plus trastuzumab. In 144 HER-2 positive breast cancer tissues, 79 cases showed high expression of MTDH and 65 cases showed low expression. The expression of MTDH in locally advanced HER-2 positive breast cancer tissues was correlated with TNM stage, lymph node metastasis, Miller-Payne (MP) grade, and pathologic complete response (pCR) status (P<.05), but was not correlated with patient age, estrogen receptor (ER) expression level, progesterone receptor (PR) expression level, and Ki-67 expression level (P>.05). Kaplan-Meier univariate analysis revealed a negative correlation between MTDH expression and the disease-free survival (DFS) and overall survival (OS) in the post-operative patients with locally advanced HER-2 positive breast cancer (log rank test: P<.001). By using the COX proportional hazard regression model, it was found that MTDH expression, TNM stage, lymph node metastasis, and Ki-67 expression were closely related to DFS in patients. The hazard ratio (HR) of high MTDH expression was 1.816 (95% CI: 1.165-2.829). In addition, MTDH expression, TNM stage, and lymph node metastasis were also closely related to the OS of patient. The HR of the high expression of MTDH was 2.512 (95% CI: 1.472-4.286). The expression of MTDH in tumor tissues of patients with HER2-positive locally advanced breast cancer was significantly elevated, which was related to the poor pathological features. High MTDH expression was closely correlated with poor prognosis of patients and was an important factor affecting tumor progression.
基金:
Youth Science and Technology Project of Hebei Provincial Health Department [20170175]
第一作者机构:[1]Hebei Med Univ, Hosp 4, Breast Ctr, Shijiazhuang, Hebei, Peoples R China
通讯作者:
通讯机构:[1]Hebei Med Univ, Hosp 4, Breast Ctr, Shijiazhuang, Hebei, Peoples R China[2]Hebei Med Univ, Hosp 4, Dept Pathol, 12 Jiankang Rd, Shijiazhuang 050035, Hebei, Peoples R China[*1]Department of Pathology, Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang 050035, China
推荐引用方式(GB/T 7714):
Wang Xinle,Cai Lijing,Ye Feng,et al.Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab[J].MEDICINE.2019,98(36):doi:10.1097/MD.0000000000016937.
APA:
Wang, Xinle,Cai, Lijing,Ye, Feng,Li, Mengqi,Ma, Li...&Liu, Yueping.(2019).Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.MEDICINE,98,(36)
MLA:
Wang, Xinle,et al."Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab".MEDICINE 98..36(2019)